The European Patent Office (EPO) has published patent application EP2026030712A1 concerning enterotoxigenic Escherichia coli multi-epitope fusion antigen proteins and their applications. This publication, dated March 18, 2026, details novel antigens and their potential uses, classified under various IPC codes including C12N 15/31 and A61K 39/108.

This patent publication does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in vaccine development or research related to E. coli infections. Companies operating in this space should monitor the patent's progress and consider its implications for their intellectual property and product development strategies.